• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Sunshine Hearts shines on $3.5 million

Sunshine Hearts shines on $3.5 million

September 20, 2010 By MedCity News

MedCity News logo

Institutional investors in the U.S. have committed to buy a $3.5 million stake in Sunshine Heart Inc. (ASX:SHC) shares in a private placement — provided the company’s Australian shareholders agree.

The medical device company — which started out in Sydney, Australia, and is now headquartered in Minneapolis — hopes to raise up to $10.3 million more through a complicated rights offering that could play out over four years, according to a press release.

Sunshine Heart is trying to commercialize the C-Pulse Heart Assist System — an implantable counter-pulsation system that does not contact the blood — to help heart failure patients. The system expands a cuff around the aorta during diastole — the relaxation part of the heartbeat — to move more blood through the body.

The company whose shares trade for a couple Australian cents on the Australian Securities Exchange received Food & Drug Administration approval to begin a 20-patient clinical feasibility trial in 2008 (PDF).

The first two moderate heart failure patients in the study were implanted at Ohio State University Medical Center in Columbus, Ohio, in April 2009 (PDF). The first severe heart failure patient in the study was implanted at Pennsylvania State University a year later (PDF).

This summer, the first minimally invasive surgery (PDF) to implant the C-Pulse system was done at the University of Louisville.

“These latest procedures accomplish our goal of successfully implanting the C-Pulse System through a mini-thoracotomy surgical method,” said Dave Rosa, Sunshine Heart’s chief executive, in an August release (PDF). “As we approach the end of our feasibility study, we are encouraged by the interest of our centers, and we remain dedicated to developing this minimally invasive, cost-effective treatment that is intended to relieve the symptoms of moderate heart failure.”

Sunshine Heart would use proceeds from its private placement and rights offering to finish its feasibility trial and six-month patient follow-up; to apply to the FDA for a larger U.S. pivotal trial; and to European authorities for CE Mark approval. The company also would use the investor money to develop its product, hire staff members for its new Minneapolis office and as working capital.

The company must file for a NASDAQ Stock Market listing as part of its private placement agreement with prospective U.S. investors.

Filed Under: Business/Financial News, News Well Tagged With: Sunshine Heart Inc.

More recent news

  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Philips prices $1.1B offering to pay off debt, finance green projects
  • Pixee Medical reports first knee arthroplasty cases using its augmented reality nav tech
  • Alpheus Medical raises $52M for ultrasound-activated tumor therapy
  • Elucent Medical wins FDA breakthrough nod for in-body spatial intelligence system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy